Skip to Content

Edwards Lifesciences Corp

EW: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$59.00NlqxkpZvyqcqqxj

Edwards Lifesciences Secures US Regulatory Approval for Transcatheter Tricuspid Valve

Business Strategy and Outlook

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical heart valves and minimally invasive valve therapy—one of the hottest areas in cardiac devices.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of EW so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center